KOREA UNITED PHARM INC
Financials
Valuation Metrics
KOREA UNITED PHARM INC's Market Cap is ₩2870B. At end of 2025 it was ₩3034B. Ranked #684 of 2,421 in KR market (top 28%), #397 of 781 on KOSPI (top 51%), #74 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 32%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 287.03B KRW | KR#684/2,421 Sec#74/231 |
| Revenue | 298.08B KRW | KR#827/2,421 Sec#38/231 |
| Net Income | 76.16B KRW | KR#308/2,421 Sec#23/231 |
| Total Assets | 570.76B KRW | KR#714/2,421 Sec#42/231 |
| Net Assets | 497.12B KRW | KR#516/2,421 Sec#31/231 |
| Employees | 936 | KR#272/2,421 Sec#21/231 |
| Value | ||
| P/E | 3.77x | KR#222/2,421 Sec#8/231 |
| P/B | 0.58x | KR#952/2,421 Sec#48/231 |
| PEG | 0.03x | KR#240/2,421 Sec#14/231 |
| P/S | 0.96x | KR#1,364/2,421 Sec#82/231 |
| EV/EBITDA | 5.23x | KR#244/2,421 Sec#4/231 |
| FCF Yield | 9.65% | KR#623/2,421 Sec#27/231 |
| Profitability | ||
| ROE | 15.32% | KR#311/2,421 Sec#20/231 |
| ROA | 13.34% | KR#156/2,421 Sec#13/231 |
| Op. Margin | 16.64% | KR#246/2,421 Sec#24/231 |
| Revenue Growth | 4.13% | KR#1,255/2,421 Sec#128/231 |
| Earnings Growth | 127.42% | KR#342/2,421 Sec#21/231 |
| Financial Health | ||
| Debt Ratio | 14.81% | KR#244/2,421 Sec#38/231 |
| Total Debt | 13.94B KRW | KR#1,517/2,421 Sec#130/231 |
| FCF | 27.69B KRW | KR#435/2,421 Sec#24/231 |
| Cash | 41.66B KRW | KR#830/2,421 Sec#51/231 |
| Current Ratio | 5.52x | KR#249/2,421 Sec#47/231 |
| Net Debt/EBITDA | -0.56x | KR#474/2,421 Sec#28/231 |
| Dividend | ||
| Div. Yield | 3.40% | KR#552/2,421 Sec#23/231 |
| Div. Growth | 35.56% | KR#320/2,421 Sec#15/231 |
| Performance | ||
| 1Y Return | -10.69% | KR#988/2,421 Sec#64/231 |
| 1M Return | 0.17% | KR#1,214/2,421 Sec#92/231 |
| From 52W High | -17.25% | KR#198/2,421 Sec#8/231 |
| 1Y MDD | -22.43% | KR#92/2,421 Sec#6/231 |
| Trading | ||
| Volume | 22,542 shares | KR#1,529/2,421 Sec#151/231 |
| Trading Value | 406.1M KRW | KR#1,008/2,421 Sec#102/231 |
| Foreign Own. | 8.93% | KR#514/2,421 Sec#43/231 |
| Per Share | ||
| EPS | 4,787 KRW | KR#225/2,421 Sec#12/231 |
| BPS | 31,244 KRW | KR#362/2,421 Sec#25/231 |
Company Info
United Pharmaceutical, a specialized pharmaceutical manufacturer established in 1987 for the manufacture and sale of pharmaceuticals, was listed on KOSDAQ in 1999 and re-listed on KOSPI in 2007. Headquartered in Jeondong-myeon, Sejong Special Self-Governing City, the company maintains 7 affiliates including United Interpharm. It sells 18 improved new drugs and new formulation products, such as the antithrombotic treatment 'Silostan CR' (approx. 15% of sales) and the dyslipidemia treatment 'Artmac Combi-Gel' (approx. 10% of sales), to medical institutions and pharmacies nationwide.